Milestone Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Milestone Pharmaceuticals generated cash of -$46,424,000, which is more than the previous year. Cash used in financing activities reached the amount of $47,792,000 last year. Net change in cash is therefore $6,124,000.
Cash Flow
| 2017 | -8.05M | -16.02M | 30.72M |
|---|---|---|---|
| 2018 | -21.04M | 15.99M | 80.11M |
| 2019 | -51.15M | -384K | 85.40M |
| 2020 | -50.73M | -70M | 73.22M |
| 2021 | -33.22M | 70M | 5.05M |
| 2022 | -52.46M | -57.12M | 3.08M |
| 2023 | -46.42M | 4.75M | 47.79M |
MIST Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 7.63M | 114.14M | 72.31M | 119.81M | 85.94M | 10.88M | 4.23M |
Operating activities | |||||||
Net income | -59.68M | -58.38M | -42.85M | -49.96M | -55.22M | -23.18M | -8.08M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 92K | 89K | 93K | 97K | 38K | 10K | 8K |
Stock-based compensation expense | 9.53M | 9.04M | 7.27M | 4.94M | 1.19M | 0 | 190K |
| Deferred income tax benefit | 9.53M | 9.04M | 7.27M | 4.94M | 1.19M | 0 | 190K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | -730K | 465K | -112K | -169K | 0 | 147K |
Inventories | 0 | 730K | -465K | 112K | 169K | 0 | 0 |
Accounts payable | 1.03M | -907K | 637K | -2.08M | 3.52M | 2.87M | -222K |
Cash generated by operating activities | -46.42M | -52.46M | -33.22M | -50.73M | -51.15M | -21.04M | -8.05M |
Investing activities | |||||||
Purchases Of Investments | -137.13M | -85.85M | -15M | -90M | -35M | -3.02M | -16.03M |
Investments In Property Plant And Equipment | -112K | -272K | 0 | 0 | -413K | -5K | -36K |
Acquisitions Net | 0 | 86.12M | 0 | 0 | 35.41M | 0 | 0 |
Cash generated by investing activities | 4.75M | -57.12M | 70M | -70M | -384K | 15.99M | -16.02M |
Financing activities | |||||||
Common Stock Issued | 574K | 2.63M | 5.05M | 24.91M | 85.36M | 0 | 30.72M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 50M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 47.79M | 3.08M | 5.05M | 73.22M | 85.40M | 80.11M | 30.72M |
Net Change In Cash | 6.12M | -106.50M | 41.83M | -47.50M | 33.87M | 75.06M | 6.64M |
Cash at end of period | 13.76M | 7.63M | 114.14M | 72.31M | 119.81M | 85.94M | 10.88M |
| Data source | Data source | Data source | Data source | Data source |